Spread of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) in general practice patients in the south of The Netherlands

M.I.A. Rijnders, P.F.G. Wolffs, R. Hopstaken, C.D.J. den Heijer, C.A. Bruggeman, E.E. Stobberingh*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


We evaluated the susceptibility to fusidic acid, mupirocin and retapamulin of Staphylococcus aureus isolated from nasal and wound swabs. The susceptibility to the three agents of S. aureus isolated from general patients in the south of The Netherlands with a skin or soft tissue infection was determined between January 2007 and December 2008. Fusidic acid-resistant isolates were tested for the presence of fusidic acid-resistant genes and compared with the epidemic European fusidic acid-resistant impetigo clone (EEFIC). Fusidic acid resistance was found in 23 of the nasal and 35 of the wound isolates, the majority (approximate to 90) being fusB positive. Most of the isolates belonged to spa type t171 and were isolated from younger patients. One isolate was retapamulin resistant (MIC 8 mg/L) and two were mupirocin resistant. The EEFIC clone was relatively highly prevalent among the isolated S. aureus. The usefulness of fusidic acid as first-line agent for the treatment of impetigo is questionable. As mupirocin is used in The Netherlands for eradication of methicillin-resistant S. aureus, it is not an alternative; retapamulin might be useful, but further in vivo studies are warranted.
Original languageEnglish
Pages (from-to)1167-1180
JournalJournal of Antimicrobial Chemotherapy
Issue number5
Publication statusPublished - 1 Jan 2012

Cite this